Wen Jin Wu

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

Cancers

Antibodies (Basel, Switzerland)

Oncoimmunology

International journal of molecular sciences

U.S. Food and Drug Administration

Cornell University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

U.S. Food and Drug Administration

United States

Senior Investigator :: Office of Biotechnology Products (OBP)

Education History

Cornell University

United States

PHD :: Molecular Medicine

Publications

Hanjing Peng, Yukinori Endo, Wen Jin Wu
Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance. Cancers 16 (13) (2024)
Hanjing Peng, Yukinori Endo, Wen Jin Wu
Define Critical Parameters of Trastuzumab-Mediated ADCC Assays via Assay Optimization Processes, Focusing on the Impact of Cryopreserved Effector Cells on Assay Performance. Cancers 16 (13) (2024)
Yukinori Endo, Katie L Winarski, Md Sanaullah Sajib, Anna Ju, Wen Jin Wu
Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. International journal of molecular sciences 24 (14) (2023)
Nishant Mohan, Atul Agrawal, Yi Shen, Katie L Winarski, Yukinori Endo, Milos Dokmanovic, Deborah Schmiel, Jiwen Zheng, David S Rotstein, Lorraine C Pelosof, Wen Jin Wu
Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1. Pharmaceutics 14 (7) (2022)
Yukinori Endo, Wen Jin Wu
Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells. Cancers 13 (10) (2021)
Nishant Mohan, Xiao Luo, Yi Shen, Zachary Olson, Atul Agrawal, Yukinori Endo, David S Rotstein, Lorraine C Pelosof, Wen Jin Wu
A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. Cancers 13 (5) (2021)
Jun Zhao, Nishant Mohan, Ruth Nussinov, Buyong Ma, Wen Jin Wu
Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers. Antibodies (Basel, Switzerland) 10 (1) (2021)
Nishant Mohan, Salman Hosain, Jun Zhao, Yi Shen, Xiao Luo, Jiangsong Jiang, Yukinori Endo, Wen Jin Wu
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells. Oncoimmunology 8 (9) (2019)

Wen Jin Wu

Publication Activity (10 Years)

Top Topics

Top Venues